Phase 3 N=97 AZMATICS: AZithroMycin/Asthma Trial In Community Settings
Asthma
Primary: Change in Overall Asthma Symptoms From Baseline — -0.60; -0.15; -0.88; -0.48 units on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=179 Varenicline for Nicotine Dependence Among Those With HIV/AIDS
Nicotine Dependence
Primary: Point Prevalence Tobacco Abstinence — 25; 11 Participants
Phase 3 N=136 Midodrine for the Treatment of Refractory Hypotension
Hypotension · Critical Illness
Primary: Time Until Discontinuation of IV Vasopressors — 23.5; 22.5 hours
Phase 3 N=245 Erlotinib or Placebo Following Chemoradiotherapy (Chemo/RT) in Stage III Non-Small Cell Lung Cancer (NSCLC)
Carcinoma, Non-Small-Cell Lung · Non-small Cell Lung Cancer · NSCLC
Primary: Progression Free Survival — 7.4; 8.1 Months — p=0.165
Phase 3 N=510 Randomized Placebo-Controlled Trial of Budesonide Multi-Matrix System (MMX®) 9 Milligrams (mg) in Participants With Ulcerative Colitis Currently on a 5-Aminosalicylic Acid (5-ASA)
Ulcerative Colitis
Primary: Number of Participants Who Achieved Clinical Remission at Day 56 — 56; 52 Participants
Phase 3 N=374 A Study Evaluating Intravenous (IV) MOA-728 for the Treatment of Postoperative Ileus (POI) in Participants After Ventral Hernia Repair
Ileus
Primary: Time to First Bowel Movement — 93.3; 100.4; 91.3 hours — p=0.944
Phase 3 N=122 Comparison of Chronocort® With Standard Glucocorticoid Therapy in Patients With Congenital Adrenal Hyperplasia
Congenital Adrenal Hyperplasia
Primary: Change From Baseline to 24 Weeks of the Mean of the 24-hour Standard Deviation Score (SDS) Profile for 17-OHP — -0.403; -0.172 Z-score — p==0.5521
Phase 3 N=451 PGL4001 Efficacy Assessment in Reduction of Symptoms Due to Uterine Leiomyomata
Uterine Fibroids
Primary: Percentage of Subjects Who Are in Amenorrhea at the End of All Four Treatment Courses — 48.7; 60.5 percentage of subjects
Phase 3 N=524 Study of Intravenous (IV) Methylnaltrexone Bromide (MNTX) in the Treatment of Post-Operative Ileus (POI)
Post-Operative Ileus (POI)
Primary: Time to First Bowel Movement — 4.4; 4.8; 4.6 days — p=0.4259
Phase 3 N=303 A Study of the Efficacy and Safety of Apremilast (CC-10004) in Subjects With Moderate to Severe Plaque Psoriasis of the Scalp
Psoriasis
Primary: Percentage of Participants With Scalp Physician Global Assessment (ScPGA) Score of Clear (0) or Almost Clear (1) With at Least a 2-Point Reduction From Baseline — 13.7…
Phase 3 N=230 Efficacy and Safety of 8-weeks of Glecaprevir/Pibrentasvir in Treatment-Naïve Adults With HCV Genotype 1-6 and Aspartate Aminotransferase to Platelet Ratio Index (APRI) ≤1
Hepatitis C Virus (HCV)
Primary: Percentage of Participants in the Modified Intention-to-Treat Population With Sustained Virologic Response 12 Weeks Post-treatment (SVR12) — 100.0 percentage of…
Phase 3 N=32 Evaluate Dental Plaque Benefit of a Preventive Treatment Gel
Dental Plaque
Primary: Mean Turesky Modified Quigley-Hein Index at Day 4 — 1.83; 1.96 score on a scale
Phase 3 N=120 Efficacy and Safety Study of Darunavir for the Treatment of HIV/AIDS
HIV/AIDS
Primary: HIV-1 RNA Viral Load — 37; 72 Participants
Phase 3 N=36 The Insulin-Only Bionic Pancreas Bridging Study
Type1 Diabetes Mellitus
Primary: Mean CGM Glucose — 144.3; 162; 155 mg/dl
Phase 3 N=1,212 Double-Blind Efficacy and Safety of CD5789 (Trifarotene) 50µg/g Cream Versus Vehicle Cream in Acne Vulgaris
Acne Vulgaris
Primary: Investigator Global Assessment (IGA) Score of 1 (Almost Clear) or 0 (Clear) — 255; 157 Participants